Benralizumab for the prevention of COPD exacerbations
<p><h4>BACKGROUND</h4></p> <p>The efficacy and safety of benralizumab, an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are n...
Үндсэн зохиолчид: | Criner, G, Celli, B, Brightling, C, Agusti, A, Papi, A, Singh, D, Sin, D, Vogelmeier, C, Sciurba, F, Bafadhel, M, Backer, V, Kato, M, Ramírez-Venegas, A, Wei, Y, Bjermer, L, Shih, V, Jison, M, O'Quinn, S, Makulova, N, Newbold, P, Goldman, M, Martin, U, Galathea and Terranova Study Investigators |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
Massachusetts Medical Society
2019
|
Ижил төстэй зүйлс
-
Predicting response to benralizumab in patients with COPD: a plain language summary of publication of the GALATHEA and TERRANOVA studies
-н: Gerard J. Criner, зэрэг
Хэвлэсэн: (2025-03-01) -
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
-н: Singh D, зэрэг
Хэвлэсэн: (2023-07-01) -
Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma
-н: O'Quinn S, зэрэг
Хэвлэсэн: (2019-01-01) -
Sputum Streptococcus pneumoniae is reduced in COPD following treatment with benralizumab
-н: George L, зэрэг
Хэвлэсэн: (2019-06-01) -
The use of benralizumab in the treatment of near fatal asthma: a new approach
-н: Ramakrishnan, S, зэрэг
Хэвлэсэн: (2020)